ABSTRACT
Anidulafungin (VER002, LY-303366; see Figure 148.1) is a semisynthetic echinocandin with broad antifungal activity against pathogenic yeasts and molds. The echinocandins were originally discovered as metabolic by-products of the fermentation process during screening programs for novel antibiotics. Anidulafungin is a derivative of the fermentation metabolite, echinocandin B0, produced by Aspergillus nidulans. The lead compound for anidulafungin was discovered in the 1970s (Benz et al., 1974) and developed at Eli Lily. The drug underwent clinical development at Vicuron Pharmaceuticals and received regulatory approval in 2006. Anidulafungin is now marketed under the brands Eraxis and Ecalta by Pfizer in the United States and Europe, respectively. Structure of anidulafungin. https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9781315152110/08d8042d-9481-4a8d-8c27-9bd589f6de6b/content/fig148_1.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/>
